Metagenomi, Inc. Common StockMGXNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
6.45%
↓ 24% below average
Average (14q)
8.45%
Historical baseline
Range
High:34.11%
Low:-11.78%
Volatility
542.9%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 6.45% |
| Q2 2025 | -10.48% |
| Q1 2025 | 8.54% |
| Q4 2024 | -11.78% |
| Q3 2024 | -7.29% |
| Q2 2024 | -9.92% |
| Q1 2024 | 27.00% |
| Q4 2023 | -7.76% |
| Q3 2023 | 18.32% |
| Q2 2023 | 12.67% |
| Q1 2023 | 33.69% |
| Q4 2022 | 34.11% |
| Q3 2022 | 33.22% |
| Q2 2022 | 0.00% |
| Q1 2022 | 0.00% |